文献速递心脑血管急症重症综合管理与镇静镇痛

蛋白S100B作为心脏骤停后早期预后判断的可靠工具

Protein S100B as a reliable tool for early prognostication after cardiac arrest.
PubMed 文献 · Resuscitation · 2020-08-25
一句话结论在心脏骤停后目标温度管理的昏迷患者中,入院时蛋白S100B预测3个月不良神经结局的AUC为0.83,优于乳酸、pH、肌酐和NSE。

这项前瞻性单中心研究纳入330例成年非创伤性心脏骤停后成功复苏的昏迷患者,均接受目标温度管理但未使用体外生命支持。在ICU入科时(ROSC后中位220分钟)及H24、H48检测乳酸、pH、肌酐、NSE和蛋白S100B,其中S100B对医生设盲。入院时S100B预测3个月良好结局(CPC1-2,109例)的AUC为0.83(95%CI 0.78-0.88),优于其他生物标志物(P<0.0001)。入院至H24期间S100B升高与3个月不良结局显著相关(P=0.001)。

要点

  • 330例心脏骤停后昏迷患者中,入院时蛋白S100B预测3个月结局的AUC为0.83(95%CI 0.78-0.88),优于乳酸、pH、肌酐和NSE(P<0.0001)。
  • 入院时所有生物标志物均与3个月良好结局(CPC1-2,109例)显著相关(P≤0.001,NSE为P=0.03)。
  • 与S100B随时间下降的患者相比,入院至H24期间S100B升高与3个月不良结局显著相关(P=0.001)。
  • 多因素分析中,无血流时间、初始不可电击心律、入院时S100B、入院时乳酸、入院时pH、临床癫痫发作和未实施治疗性低温是3个月不良结局的独立预测因素。
  • 将入院时S100B加入临床模型、临床+NSE模型、临床+标准生物学参数模型时,净重分类指数分别为70%、64%和81%。

适用人群与场景

  • 纳入:330例成年非创伤性心脏骤停后成功复苏的昏迷患者,接受目标温度管理但未使用体外生命支持。
  • 场景:ICU入科时(ROSC后中位220分钟)及H24、H48进行生物标志物检测。
  • 随访:3个月。

诊断标准与关键阈值

  • 良好结局定义为3个月随访时CPC1-2(109例)。
  • 不良结局与入院至H24期间S100B升高相关(P=0.001)。

研究设计与关键结果

  • 研究类型:前瞻性单中心研究,样本量330例,人群为成年非创伤性心脏骤停后昏迷患者,干预为目标温度管理(未使用体外生命支持),检测乳酸、pH、肌酐、NSE和蛋白S100B(S100B对医生设盲)。
  • 主要终点:入院时S100B预测3个月结局的AUC为0.83(95%CI 0.78-0.88),优于其他生物标志物(P<0.0001);入院时乳酸AUC高于入院时NSE。
  • H24时S100B的AUC显著高于除NSE-H24外的其他生物标志物(P≤0.0001);NSE-H24的AUC高于乳酸-H24和pH-H24。
  • H48时S100B和NSE的AUC均显著高于其他所有生物标志物(P<0.001)。
  • 入院至H24期间S100B升高与3个月不良结局显著相关(P=0.001)。
  • 多因素分析:无血流时间、初始不可电击心律、入院时S100B、入院时乳酸、入院时pH、临床癫痫发作和未实施治疗性低温是3个月不良结局的独立预测因素。
  • 净重分类指数:加入入院时S100B至临床模型为70%,至临床+NSE模型为64%,至临床+标准生物学参数模型为81%。

证据类型、等级与局限

  • 证据类型:前瞻性单中心研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 入院时蛋白S100B可用于心脏骤停后昏迷患者早期预后评估,其预测3个月神经结局的区分度优于乳酸、pH、肌酐和NSE。
  • 入院至H24期间S100B升高提示不良结局风险增加。
  • 将S100B加入现有临床预测模型可提高重分类能力(净重分类指数70%-81%)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Early and reliable prognostication after cardiac arrest (CA) remains crucial. We hypothesized that protein-S100B (PS100B) could predict more accurately outcome in the early phase of CA compared with other current biomarkers.

METHODS: This prospective single-center study included 330 adult comatose non-traumatic successfully resuscitated CA patients, treated with targeted temperature management but not extra-corporeal life support. Lactate, pH, creatinine, NSE, and PS100B were sampled in ICU early after return of spontaneous circulation (ROSC) corresponding to admission (Adm). Serial measurements were also performed at H24 and H48. PS100B was the sole biomarker blinded to physicians.

MEASUREMENTS AND MAIN RESULTS: The median delay between ROSC and first PS100B sampling was 220 min. At admission, all biomarkers were significantly associated with good outcome (CPC1-2; 109 patients) at 3-month follow-up (P ≤ 0.001, except for NSE: P = 0.03). PS100B-Adm showed the best AUC of ROC curves for outcome prediction at 3-month (AUC 0.83 [95%-CI: 0.78-0.88]), compared with other biomarkers (P < 0.0001), while AUC for lactate-Adm was higher than for NSE-Adm. AUC for PS100B-H24 was significantly higher than for other biomarkers except NSE-H24 (P ≤ 0.0001), while AUC for NSE-H24 was higher than for lactate-H24 and pH-H24. AUCs for PS100-H48 and NSE-H48 were significantly higher than for all other biomarkers (P < 0.001). Compared to patients with decreased PS100B values over time, an increasing PS100B value between admission and H24 was significantly associated with poor outcome at 3 months (P = 0.001). No-flow, initial non-shockable rhythm, PS100B-Adm, lactate-Adm, pH-Adm, clinical seizures, and absence of therapeutic hypothermia were independent predictors associated with poor outcome at 3-month in multivariate analysis. Net-Reclassification-Index was 70%, 64%, and 81% when PS100B-Adm was added to the clinical model, to clinical model with NSE-Adm, and to clinical model with standard biological parameters, respectively.

CONCLUSIONS: Early PS100B compared with other biomarkers was independently correlated with outcome after CA, with an interesting added value.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Deye N, Nguyen P, Vodovar N, et al. Protein S100B as a reliable tool for early prognostication after cardiac arrest. Resuscitation. 2020. PMID: 32858156. doi:10.1016/j.resuscitation.2020.08.010

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。